DEF: OSR Holdings: Shareholder Vote on Dilution, Equity Plan

OSR Holdings, Inc. is seeking shareholder approval for the election of seven directors, an advisory vote on executive compensation, the adoption of new equity incentive plans, and a significant common share issuance that could exceed 20% of outstanding stock, potentially leading to dilution.

Summary

• An Annual Meeting of Stockholders is scheduled for September 17, 2025, to vote on four key proposals.
• Proposals include the election of seven directors, a non-binding advisory vote on named executive officer compensation, approval of compensation terms and adoption of share-based incentive sub-plans under the 2025 Omnibus Incentive Plan, and approval to issue common shares exceeding 20% of outstanding stock.
• The 20% share issuance proposal is necessary to comply with Nasdaq Listing Rule 5635(d) in connection with an existing Equity Line of Investment (ELOC) Agreement with White Lion GBM Innovation Fund, which allows White Lion to purchase up to $78,900,000 in shares.
• The ELOC also includes a WL Warrant Agreement for White Lion to purchase up to $4,000,000 worth of common stock at an exercise price of $1.584, and a Note Purchase Agreement for a $1,110,000 loan via convertible promissory notes.
• The 2025 Omnibus Incentive Plan reserves 6,300,000 shares for equity awards, split equally between Restricted Stock Units (RSUs) and Stock Options, featuring both default and accelerated vesting schedules tied to business development transaction values.
• The Board of Directors unanimously recommends a vote FOR all four current proposals.

Sentiment

Score: 4

Explanation: While the company is establishing a robust equity incentive plan and securing capital, the explicit warning of significant dilution and potential stock price decline from the proposed share issuance, coupled with a CEO resignation, introduces notable negative sentiment. The capital raise is necessary but comes at a cost to existing shareholders.

Positives

• Establishment of a 2025 Omnibus Incentive Plan with 6,300,000 shares available, designed to attract, retain, and motivate employees, directors, and consultants.
• The equity incentive plans include accelerated vesting provisions tied to significant business development transactions (ranging from $300M to $1B), aligning incentives with company growth and strategic milestones.
• Secured an Equity Line of Investment (ELOC) with White Lion GBM Innovation Fund for up to $78,900,000, providing a potential source of capital for future operations.
• Obtained a loan of $1,110,000 from White Lion via Senior Secured Convertible Promissory Notes, providing immediate capital at a 5% annual interest rate.

Negatives

• The Nasdaq 20% Issuance Proposal explicitly states it will have a dilutive effect on existing stockholders, including their voting power and economic rights, and may result in a decline in stock price or greater price volatility in the short term.
• The issuance price for the 20% common share issuance may be less than the lower of the Nasdaq Official Closing Price or the average Nasdaq Official Closing Price for the five trading days immediately preceding the signing of the binding agreement, indicating potential issuance at a discount.
• Executive compensation for the CEO and Chairman was $0 for 2024, with the former CEO receiving $84,020, which could raise questions about executive incentives or the compensation structure.
• Sang Hoon Kim, the former Chief Executive Officer, resigned as of August 26, 2025, due to changes in the company's business plan and other governance-related reasons, which could signal internal instability or strategic shifts.

Risks

• Dilution of existing stockholders' voting power and economic rights due to the potential issuance of shares exceeding 20% of outstanding common stock to White Lion.
• Potential decline in stock price or greater price volatility in the short term resulting from the issuance of a large number of shares to White Lion.
• Financing risks associated with reliance on the ELOC agreement and convertible notes, which may not be fully utilized or could be subject to market conditions affecting the conversion price.
• Exposure to international, national, and local economic conditions, merger, acquisition, and business combination risks, and geo-political risks, acts of terror or war, as outlined in previous SEC filings.

Future Outlook

The company intends to consider issuing equity-based awards in future periods as part of its strategy to attract and retain key personnel. The 2025 Omnibus Incentive Plan is designed to provide incentives for long-term growth and profitability and to recruit, reward, and retain key personnel. The company also has an equity line of investment with White Lion GBM Innovation Fund, providing a potential source of future capital.

Management Comments

• Our Board has determined that the Current Proposals are advisable and recommends that you vote or give instruction to vote FOR the Current Proposals.
• We do not believe his resignation causes any material impact on the Company's business and operation. (Regarding Sang Hoon Kim's resignation)

Industry Context

The company operates in the biopharmaceutical industry, as indicated by the background of several directors and its previous name. The adoption of a comprehensive equity incentive plan is a common practice in growth-oriented industries like biotech to attract and retain talent, especially given the long development cycles and high-risk nature of drug development. The pursuit of an equity line of credit and convertible notes suggests a need for capital, which is also common for biopharmaceutical companies in various stages of development.

Comparison to Industry Standards

• The 4-year vesting with a 1-year cliff for equity awards is a common industry standard for employee retention in many sectors, including biotech.
• The use of performance-based accelerated vesting tied to business development transactions (e.g., $300M to $1B contracted value) is a strong incentive mechanism, often seen in biotech to reward successful partnerships or licensing deals, which are critical milestones for drug development companies.
• The potential for significant dilution (exceeding 20%) through an equity line of credit and convertible notes, especially at a discount to market price, is a common financing method for smaller, growth-stage companies, particularly in capital-intensive industries like biotech, where traditional debt financing might be less accessible or more expensive. However, such dilution is generally viewed negatively by existing shareholders and can be more substantial than typical follow-on offerings by more mature companies.

Management Changes

Corporate Governance

Related Party Transactions

• The Company pays Bellevue Capital Management LLC (BCM) $7,500 per month for office space, utilities, and secretarial/administrative support.
• Kuk Hyoun Hwang, the CEO and Chairman, is the founder and managing partner of BCM and the general partner of Bellevue Global Life Sciences Investors LLC (BGLSI), holding significant voting and dispositive power over shares held by these entities.
• In 2023, the Company's Sponsor (BGLSI) transferred 20,000 founder shares to several directors and the former CFO, and 20,000 private placement warrants to the former chairman of the board, audit committee chair, and former CFO.
• Jun Chul Whang, Chief Legal Officer and Director, is a minority owner of BCM but has no voting or dispositive power over BGLSI shares.

Stakeholder Impact

• Shareholders will experience dilution of voting power and economic rights if the Nasdaq 20% Issuance Proposal is approved, potentially leading to a decline in stock price or increased volatility. They also have the opportunity to vote on key governance matters, including director elections and executive compensation.
• Employees, Directors, Advisors, and Contractors will be eligible to receive equity-based awards (Restricted Stock Units and Stock Options) under the new 2025 Omnibus Incentive Plan, providing incentives for long-term performance and retention.
• White Lion GBM Innovation Fund will gain the right to purchase a significant amount of common stock and convert promissory notes, becoming a substantial investor and potentially influencing the company's capital structure.
• Management's incentives and potential future earnings are directly impacted by the executive compensation structure and the new equity plan. The resignation of the former CEO indicates a change in the management team.

Next Steps

• Stockholders to vote on the four proposals at the Annual Meeting on September 17, 2025.
• The company will file a Current Report on Form 8-K with the SEC within four business days following the Annual Meeting to announce final voting results.
• The company may consider issuing equity-based awards in future periods as part of its strategy to attract and retain key personnel.
• The 2025 Omnibus Incentive Plan will terminate on the day before the tenth anniversary of its effective date (January 29, 2025).
• The Common Stock Purchase Agreement with White Lion will terminate on the earlier of December 31, 2026, or company bankruptcy events.

Key Dates

Recommendation

The filing outlines necessary corporate governance actions and a significant capital raise mechanism. While the capital infusion from White Lion is positive for funding future operations, the explicit warning of substantial dilution (exceeding 20% of outstanding shares) and potential stock price volatility for existing shareholders is a major concern. The resignation of the former CEO also adds a layer of uncertainty. Investors should hold to monitor the execution of the capital raise, the impact of dilution on the stock price, and the company's strategic direction post-CEO change, before making further investment decisions.

Keywords

OSR Holdings, SEC filing, proxy statement, annual meeting, director election, executive compensation, equity plan, stock options, restricted stock units, RSU, stock appreciation rights, SAR, Nasdaq listing rules, share issuance, dilution, White Lion, equity line of investment, ELOC, convertible notes, corporate governance, risk factors, biopharmaceutical, healthcare investment